ARTICLE | Product Development
Nektar, BMS terminate combo’s development after another pair of misses
Failures in renal, bladder cancers closely follow Phase III miss for bempegaldesleukin plus Opdivo in first-line melanoma
April 14, 2022 10:56 PM UTC
The failure of Nektar’s IL-2 program in two more clinical trials extinguishes hopes for a four-year-old partnership in which BMS paid $1 billion up front to explore combinations with oncology blockbuster Opdivo.
Nektar Therapeutics (NASDAQ:NKTR) said late Thursday that bempegaldesleukin plus PD-1 inhibitor Opdivo nivolumab from Bristol Myers Squibb Co. (NYSE:BMY) did not meet criteria to show clinical benefit compared with the control arm in the Phase III PIVOT-09 study as first-line therapy for renal cell carcinoma...